This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,032,192 to Yale University to conduct research on the cell-type specific epigenomic effects of cannabis use in people living with HIV. The project aims to dissect the interactions between HIV infection and cannabis use, and identify potential druggable targets through comprehensive profiling of DNA methylation across different cell types. The...
This $441,000 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research at Yale University to investigate the molecular changes in the brain that link cannabis use disorder and major depressive disorder. The researchers will use innovative single-cell genomics to identify transcriptomic and chromatin alterations in two key brain regions from 120 donors with cannabis use disorder, major...
This $196,350 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Yale University. The grant will fund a project titled "HIV COMPLEX CAUSAL MODELING: GUT MICROBIOME, DRUG USE, AND IMMUNE RESPONSES" from August 1, 2024 to July 31, 2026. The project aims to elucidate the causal relationship between drug use disorders, HIV acquisition, gut microbiome, and immune responses using Mendelian randomization...
This Project Grant award of $1,838,237, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the neuronal circuits through which chronic stress promotes habit formation. The award, effective September 15, 2024 and ending May 31, 2029, will be executed by the University of California, Los Angeles (UCLA). The research aims to expose how opposing amygdala-striatal pathways in the brain enable...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,223,769 to the University of California, San Diego (UCSD) to conduct research on the intertwined mechanisms of HIV and opioid use on mitochondrial-mediated inflammasome activation and neurotoxicity. The research aims to elucidate how the convergence of HIV infection and opioid use leads to more severe neurological consequences, including...
This Project Grant award of $558,668 from the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs supports research to elucidate the shared and distinct molecular mechanisms underlying the interplay between HIV, substance use disorders (SUD), and neuropsychiatric/neurodegenerative conditions. The award to Massachusetts Institute of Technology (MIT) aims to leverage single-cell transcriptomic, epigenomic, and spatial datasets along with...
This $181,040 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to create an immersive training experience to study the genetic etiology of substance use disorders (SUDs). The award recipient, Yale University, will leverage the Million Veteran Program (MVP) biobank to: (1) model patterns of SUD co-occurrence and substance co-use, (2) utilize electronic health record data and toxicology results to provide...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $569,743 to Yale University to conduct the "Y-SCORCH 2.0" research project. The goal is to further analyze transcriptomic and epigenetic data from the SCORCH consortium to identify potential treatment targets for the intersection of opioid use disorder (OUD) and HIV, which together affect over 20 million individuals globally. The key products and services...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,940,518 to Wake Forest University Health Sciences (WFUHS) to conduct a randomized controlled trial (RCT) investigating neuroimmune mechanisms linking psychosocial stress, stimulant use, and depression in people living with HIV (PWH). The study aims to (1) examine the impact of a positive affect intervention (ARTEMIS) on neural...
This Project Grant award of $769,708 was provided by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research to assess self-efficacy, perceived peer and familial norms, and motivation to reduce alcohol and/or cannabis use and engage in treatment referral among assault-injured emerging adults. The research aims to adapt and pilot test a Brief Negotiation Interview (BNI) intervention for use in the...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $3,580,802 to Yale University to conduct research on stress-immune mechanisms in people living with HIV, cannabis use disorder, and depression. The key goals are to:
Determine the hypothalamic-pituitary-adrenal (HPA) and immune response to acute stress among healthy controls, people living with HIV, and those with complex morbidity (HIV, cannabis use disorder, and major depressive disorder).
Identify cell-type epigenetic regulation of HPA-immune response to acute stress across the three groups by profiling DNA methylation and gene expression.
Link acute stress HPA-immune dysregulation to retrospective stress, prospective daily distress, and complex morbidity symptoms using ecological momentary assessment.
The research aims to elucidate the psychobiological-epigenomic mechanisms underlying complex morbidities in people living with HIV and identify potential stress biomarkers. A sub-award of $80,005 was provided to New York University to contribute genomics data and analysis from the Multicenter AIDS Cohort Study. The project period runs from September 2024 to May 2029.